**Development of a Novel HIV Bi-functional Therapeutic**

**OCR Number:** OCR 5484

**Description:**

- Specifically both HIV (or HIV-infected CD4 T cells) and endogenous, well characterized, antibodies (anti-DNP).
- Blocks HIV entry into cells as well as recruits antibodies.
- Results in destruction of HIV and/or HIV-infected cells.
- Provides advantages over protein-based therapeutics, such as large-scale production capabilities and low cost.
- ARM-H-3 is a soluble drug-like compound derivative of a known HIV antagonist.

**Figure**: HIV-1 viral replication assay. UV absorption at 595 nm, increased by the metabolic action of live MT-2 (CD4+) cells on an assay reagent (MTT), is monitored as a surrogate for cell viability in the presence of increasing concentrations of ARM-H-3 alone (white circles), or ARM-H-3 plus live HIV-1 virus (black circles)

**Licensing Contact:** David Lewin
david.lewin@yale.edu